Search CTL/CD8+ T-Cell Epitope Database

Found 23 matching records:

Displaying record number 1368

HXB2 Location	Gag(24-32) p17(24-32) DNA(859..885)	Gag Epitope Map
Author Location	p17(24-32)
Epitope	`GGKKKYKLK`	Epitope Alignment
Epitope Name	GGK
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
This epitope was recognized by 1/7 study subjects that were HLA-B8+.
Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK -- GEIYKRWII and GGKKKYKLK responses were stimulated by a brief period off therapy.

References

Oxenius2000b A. Oxenius, D. A. Price, P. J. Easterbrook, C. A. O'Callaghan, A. D. Kelleher, J. A. Whelan, G. Sontag, A. K. Sewell, and R. E. Phillips. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U.S.A., 97(7):3382-7, 28 Mar 2000. URL: http://www.pnas.org/cgi/content/full/97/7/3382. PubMed ID: 10737796. Show all entries for this paper.

Displaying record number 1367

HXB2 Location	Gag(71-79) p17(71-79) DNA(1000..1026)	Gag Epitope Map
Author Location	p17(71-79 HXB2)
Epitope	`GSEELRSLY`	Epitope Alignment
Epitope Name	GSE
Subtype	B
Species (MHC/HLA)	human(A1)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
This epitope was not recognized by the 6/8 study subjects that were HLA-A1.

References

Displaying record number 1381

HXB2 Location	Gag(147-155) p24(15-23) DNA(1228..1254)	Gag Epitope Map
Author Location	p24(147-155)
Epitope	`ISPRTLNAW`	Epitope Alignment
Epitope Name	ISP
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B57+.

References

Displaying record number 1380

HXB2 Location	Gag(162-172) p24(30-40) DNA(1273..1305)	Gag Epitope Map
Author Location	p24(162-172)
Epitope	`KAFSPEVIPMF`	Epitope Alignment
Epitope Name	KAF
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B57+.

References

Displaying record number 1378

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location	p24(108-117)
Epitope	`TSTLQEQIGW`	Epitope Alignment
Epitope Name	TST
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B57+.

References

Displaying record number 1384

HXB2 Location	Gag(254-262) p24(122-130) DNA(1549..1575)	Gag Epitope Map
Author Location	p24(260-268)
Epitope	`PPIPVGDIY`	Epitope Alignment
Epitope Name	PPI
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
One of two HLA B35+ among the eight study subjects recognized this epitope.
Patient SC15 (HLA A1/68, B8/35, Bw4/6, Cw4/0704) was given acute and sustained therapy and recognized epitopes PPIPVGDIY and VPLRPMTY during 331 days of HAART treatment.

References

Displaying record number 1376

HXB2 Location	Gag(259-267) p24(127-135) DNA(1564..1590)	Gag Epitope Map
Author Location	p24(259-267)
Epitope	`GEIYKRWII`	Epitope Alignment
Epitope Name	GEI
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, escape, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
Six of the 7/8 study subjects that were HLA B8 recognized this epitope.
Patient SC2 (HLA A1, B7/8, Cw0701/0702, DR4/53, DQ7) had CTL responsiveness against epitopes FLKEKGGL, GPKVKQWPL, and GEIYKRWII peptides -- FLKEKGGL tetramer staining steadily declined and at day 1340 the FLKEKGGL stained cells were no longer detected and the escape mutant FLKENGGI was found in 8/10 clones.
Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV, SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII and all responses declined during therapy initiated at day 390 but were restored when therapy become intermittent.
Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII, ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197.
Patient SC10(HLA A1/3, B8/35, DR1/8, DQ 4/5) had sustained therapy started during acute infection and maintained an immunodominant response to FLKEKGGL and a response to GEIYKRWII through day 1088.
Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK -- GEIYKRWII and GGKKKYKLK responses were stimulated by a brief period off therapy.
Patient SC11(HLA A1, B8, Cw0201, DR3/11, DR52, DQ2/7) started therapy early, remained on therapy for 40 days, then reinitiated HAART at day 640 had a CTL response to FLKEKGGL, GPKVKQWPL, and GEIYKRWII throughout and received a benefit from the early limited course therapy.

References

Displaying record number 1386

HXB2 Location	Gag(325-333) p24(193-201) DNA(1762..1788)	Gag Epitope Map
Author Location	p24(323-333)
Epitope	`NANPDCKTI`	Epitope Alignment
Epitope Name	NAN
Species (MHC/HLA)	human(B51)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B51+

References

Displaying record number 1374

HXB2 Location	Gag(329-337) p24(197-205) DNA(1774..1800)	Gag Epitope Map
Author Location	p24(329-337)
Epitope	`DCKTILKAL`	Epitope Alignment
Epitope Name	DCK
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
This epitope was recognized at a low level by only 1 of the 7/8 study subjects that were HLA B8.
Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK -- GEIYKRWII and GGKKKYKLK responses were stimulated by a brief period off therapy.

References

Displaying record number 1370

HXB2 Location	Gag(349-359) p24(217-227) DNA(1834..1866)	Gag Epitope Map
Author Location	p24(349-359)
Epitope	`ACQGVGGPGHK`	Epitope Alignment
Epitope Name	ACQ
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Patient MHC/HLA	SC19: A11, A29, B08, B44, Cw06, Cw0701, DQ2, DQ8, DR3, DR52, DR53, DR7; SC18: A02, A11, B50, B58, Bw4, Bw6, Cw*0401, Cw10, DQ2, DQ8, DR3, DR4, DR52, DR53
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
Both of the 2/8 HLA-A11 study subjects recognized this CTL epitope.
Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII, ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197.
Patient SC18(HLA A2/11, B8/44, Cw06/0701, DR3/7, DR52/53, DQ2) recognizes the epitopes ACQGVGGPGHK, QVPLRPMTYK, AVDLSHFLK, and one called QIY but not fully described -- he had brief therapy upon seroconversion and has had low viral load during 600 days of follow up.

References

Displaying record number 1377

HXB2 Location	Pol(173-181) RT(18-26) DNA(2601..2627)	Pol Epitope Map
Author Location	RT(185-193)
Epitope	`GPKVKQWPL`	Epitope Alignment
Epitope Name	GPK
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, escape, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
Two of the 7/8 study subjects that were HLA B8+ recognized this epitope.
Patient SC2 (HLA A1, B7/8, Cw0701/0702, DR4/53, DQ7) had CTL responsiveness against epitopes FLKEKGGL, GPKVKQWPL, and GEIYKRWII peptides -- FLKEKGGL tetramer staining steadily declined and at day 1340 the FLKEKGGL stained cells were no longer detected and the escape mutant FLKENGGI was found in 8/10 clones.
Patient SC11(HLA A1, B8, Cw0201, DR3/11, DR52, DQ2/7) started therapy early, remained on therapy for 40 days, then reinitiated HAART at day 640 had a CTL response to FLKEKGGL, GPKVKQWPL, and GEIYKRWII throughout and received a benefit from the early limited course therapy.

References

Displaying record number 1387

HXB2 Location	Pol(283-290) RT(128-135) DNA(2931..2954)	Pol Epitope Map
Author Location	RT(295-302)
Epitope	`TAFTIPSI`	Epitope Alignment
Epitope Name	TAF
Species (MHC/HLA)	human(B51)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B51+

References

Displaying record number 1379

HXB2 Location	Pol(398-407) RT(243-252) DNA(3276..3305)	Pol Epitope Map
Author Location	RT(410-419)
Epitope	`PIVLPEKDSW`	Epitope Alignment
Epitope Name	PIV
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B57+

References

Displaying record number 1369

HXB2 Location	Pol(464-472) RT(309-317) DNA(3474..3500)	Pol Epitope Map
Author Location	RT(476-484)
Epitope	`ILKEPVHGV`	Epitope Alignment
Epitope Name	ILK
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
One of the 2/8 HLA-A2+ study subjects recognized this CTL epitope.
Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV, SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII peptides and all responses declined during therapy initiated at day 390 but were restored when therapy become intermittent.

References

Displaying record number 1373

HXB2 Location	gp160(376-384) gp120(376-384) DNA(7350..7376)	gp160 Epitope Map
Author Location	gp120(376-384)
Epitope	`FNCGGEFFY`	Epitope Alignment
Epitope Name	FNC
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
One of the 7/8 study subjects that were HLA B8 recognized this CTL epitope.
Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII, ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197.

References

Displaying record number 1388

HXB2 Location	gp160(557-565) gp41(46-54) DNA(7893..7919)	gp160 Epitope Map
Author Location	gp41(557-565)
Epitope	`RAIEAQQWQ`	Epitope Alignment
Epitope Name	RAI
Species (MHC/HLA)	human(B51)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B51+

References

Displaying record number 1372

HXB2 Location	Nef(73-82) DNA(9013..9042)	Nef Epitope Map
Author Location	Nef(73-82)
Epitope	`QVPLRPMTYK`	Epitope Alignment
Epitope Name	QVP
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
One of the 2/8 HLA-A11 study subjects recognized this CTL epitope.
Patient SC18(HLA A2/11, B8/44, Cw06/0701, DR3/7, DR52/53, DQ2) recognizes the epitopes ACQGVGGPGHK, QVPLRPMTYK, AVDLSHFLK, and one called QIY but not fully described -- he had brief therapy upon seroconversion and has had low viral load during 600 days of follow up.

References

Displaying record number 1385

HXB2 Location	Nef(74-81) DNA(9016..9039)	Nef Epitope Map
Author Location	Nef(74-81)
Epitope	`VPLRPMTY`	Epitope Alignment
Epitope Name	VPL
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
One of two HLA B35+ among the eight study subjects recognized this epitope.
Patient SC15 (HLA A1/68, B8/35, Bw4/6, Cw4/0704) was given acute and sustained therapy and recognized epitopes PPIPVGDIY and VPLRPMTY during 331 days of HAART treatment.

References

Displaying record number 1371

HXB2 Location	Nef(84-92) DNA(9046..9072)	Nef Epitope Map
Author Location	Nef(84-92)
Epitope	`AVDLSHFLK`	Epitope Alignment
Epitope Name	AVD
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
Both of the 2/8 HLA-A11 study subjects recognized this CTL epitope.
Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII, ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197.
Patient SC18(HLA A2/11, B8/44, Cw06/0701, DR3/7, DR52/53, DQ2) recognizes the epitopes ACQGVGGPGHK, QVPLRPMTYK, AVDLSHFLK, and one called QIY but not fully described -- he had brief therapy upon seroconversion and has had low viral load during 600 days of follow up.

References

Displaying record number 1375

HXB2 Location	Nef(90-97) DNA(9064..9087)	Nef Epitope Map
Author Location	Nef(92-99)
Epitope	`FLKEKGGL`	Epitope Alignment
		Show epitope variants
Epitope Name	FLK
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), immunodominance, escape, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
Six of the 7/8 study subjects that were HLA B8 recognized this early dominant CTL epitope.
Patient SC2 (HLA A1, B7/8, Cw0701/0702, DR4/53, DQ7) had CTL responsiveness against epitopes FLKEKGGL, GPKVKQWPL, and GEIYKRWII peptides -- FLKEKGGL tetramer staining steadily declined and at day 1340 the FLKEKGGL stained cells were no longer detected and the escape mutant FLKENGGI was found in 8/10 clones.
Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV, SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII peptides and all responses declined during therapy initiated at day 390 but were restored when therapy become intermittent.
Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII, ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197.
Patient SC10(HLA A1/3, B8/35, DR1/8, DQ 4/5) had sustained therapy started during acute infection and maintained an immunodominant response to FLKEKGGL and a response to GEIYKRWII through day 1088.
Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK -- GEIYKRWII and GGKKKYKLK responses were stimulated by a brief period off therapy.
Patient SC11(HLA A1, B8, Cw0201, DR3/11, DR52, DQ2/7) started therapy early, remained on therapy for 40 days, then reinitiated HAART at day 640 had a CTL response to FLKEKGGL, GPKVKQWPL, and GEIYKRWII throughout and received a benefit from the early limited course therapy.

References

Displaying record number 1382

HXB2 Location	Nef(103-127) DNA(9103..9177)	Nef Epitope Map
Author Location	Nef(103-127)
Epitope	`SQRRQDILDLWIYHTQGYFPDWQNY`	Epitope Alignment
Epitope Name	SQR
Species (MHC/HLA)	human(B13)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
The only study subject out of eight that was HLA B13+ recognized this epitope.
Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV, SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII peptides and all responses declined during therapy initiated at day 390 but were restored when therapy become intermittent.

References

Displaying record number 1389

HXB2 Location	Nef(116-125) DNA(9142..9171)	Nef Epitope Map
Author Location	Nef(116-125)
Epitope	`HTQGYFPDWQ`	Epitope Alignment
Epitope Name	HTQ
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B57+

References

Displaying record number 1383

HXB2 Location	Nef(134-144) DNA(9196..9228)	Nef Epitope Map
Author Location	Nef(134-144)
Epitope	`RYPLTFGWCYK`	Epitope Alignment
Epitope Name	RYP
Species (MHC/HLA)	human(B18)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
None of the 8 study subjects recognized this epitope but none were HLA B18+